Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

<p>Supplementary Dataset S9</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Cara Abecunas (14960274) (author)
Kolejni autorzy:	Christopher E. Whitehead (14960277) (author), Elizabeth K. Ziemke (14960280) (author), Douglas G. Baumann (14960283) (author), Christy L. Frankowski-McGregor (14960286) (author), Judith S. Sebolt-Leopold (14960289) (author), Mohammad Fallahi-Sichani (14960292) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Drug Targets Skin Cancers Melanoma Small Molecule Agents Kinase inhibitors Systems Biology
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Dataset S1 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S2 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S3 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S4 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S5 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S6 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S7 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Dataset S8 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
od: Cara Abecunas (14960274)
Wydane: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
od: James S. Wilmott (15008931)
Wydane: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
od: James S. Wilmott (15008931)
Wydane: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Wydane: (2025)

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.
od: Fengyi Mao (15073242)
Wydane: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Wydane: (2025)

Polo-like kinase 1 (PLK1) is involved in melanoma progression.
od: Fengyi Mao (15073242)
Wydane: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Wydane: (2025)

Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.
od: Fengyi Mao (15073242)
Wydane: (2025)

Supplementary Table 1 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
od: Nneoma Adaku (16991063)
Wydane: (2025)

Supplementary Table 2 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
od: Nneoma Adaku (16991063)
Wydane: (2025)

Supplementary Table 3 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
od: Nneoma Adaku (16991063)
Wydane: (2025)

Overexpressed Polo-like kinase 1 (PLK1) promotes metastasis and metabolic reprogramming in melanoma.
od: Fengyi Mao (15073242)
Wydane: (2025)

Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S7 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Table 3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
od: Andrew W. Hahn (15024693)
Wydane: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
od: Alexander N. Shoushtari (15023909)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_48bon9fpjhknck1710cf1tastr